Masuo M, Shimada T, Kitazawa T
Department of Physiology, University of Virginia School of Medicine, Charlottesville.
J Pharmacol Exp Ther. 1992 Mar;260(3):1300-8.
The mechanism of inhibitory effects of azelastine, an antiallergic and antiasthmatic agent, on depolarization- and alpha-1 adrenergic agonist-induced contractions of intact smooth muscle was studied. The effects of azelastine on membrane currents were determined in isolated guinea pig ileum smooth muscle cells with the whole-cell clamp technique; the effects on contraction were evaluated in receptor- and G-protein-coupled, alpha-toxin-permeabilized rabbit femoral artery and portal vein smooth muscle strips. Azelastine (1-20 microM), like dihydropyridines, inhibited spontaneous rhythmic and high K(+)-induced contractions, mainly through inhibition of the voltage-dependent (L-type) Ca++ current. The tonic component of high K+ contractions was inhibited more than the phasic component, correlating to voltage-dependent inhibition of Ca++ current by the drug. Azelastine (IC50 of 0.25 microM), a known histamine blocker, also reversibly inhibited alpha-1 agonist-induced contractions in the presence and absence of extracellular Ca++. Both major pathways of pharmacomechanical coupling, agonist-induced Ca++ release from the sarcoplasmic reticulum and Ca++ sensitization of the regulatory/contractile apparatus were blocked by the same concentration of drug in permeabilized as in intact muscle. Inositol 1,4,5-trisphosphate-induced Ca++ release and guanosine 5'-O-(tau-thiotriphosphate)-induced Ca++ sensitization, however, were not inhibited. Azelastine at high (greater than 10 microM) concentrations reversibly inhibited Ca(++)-activated contraction, more potently at lower Ca++ concentration and in phasic smooth muscle, but inhibited neither adenosine 5'-O-(tau-thiotriphosphate)-induced, Ca(++)-independent nor phorbol ester-induced contractions. These results indicate that azelastine is a genuine Ca++ antagonist that inhibits voltage-gated Ca++ inward current and agonist-induced Ca++ release and Ca++ sensitization.
研究了抗组胺和抗哮喘药氮卓斯汀对完整平滑肌去极化和α-1肾上腺素能激动剂诱导收缩的抑制作用机制。采用全细胞膜片钳技术测定了氮卓斯汀对豚鼠离体回肠平滑肌细胞膜电流的影响;在受体和G蛋白偶联、α-毒素通透的兔股动脉和门静脉平滑肌条上评估了其对收缩的影响。氮卓斯汀(1-20μM)与二氢吡啶类药物一样,主要通过抑制电压依赖性(L型)Ca++电流来抑制自发性节律性收缩和高钾诱导的收缩。高钾收缩的强直成分比相性成分受到的抑制更明显,这与该药物对Ca++电流的电压依赖性抑制相关。作为一种已知的组胺阻滞剂,氮卓斯汀(IC50为0.25μM)在有无细胞外Ca++的情况下均可可逆地抑制α-1激动剂诱导的收缩。在通透和平整的肌肉中,相同浓度的药物均可阻断药物机械偶联的两条主要途径,即激动剂诱导的肌浆网Ca++释放和调节/收缩装置的Ca++致敏。然而,肌醇1,4,5-三磷酸诱导的Ca++释放和鸟苷5'-O-(τ-硫代三磷酸)诱导的Ca++致敏并未受到抑制。高浓度(大于10μM)的氮卓斯汀可可逆地抑制Ca(++)激活的收缩,在较低Ca++浓度和相性平滑肌中作用更强,但对腺苷5'-O-(τ-硫代三磷酸)诱导的、Ca(++)非依赖性收缩或佛波酯诱导的收缩均无抑制作用。这些结果表明,氮卓斯汀是一种真正的Ca++拮抗剂,可抑制电压门控Ca++内向电流以及激动剂诱导的Ca++释放和Ca++致敏。